{"id":15459,"date":"2023-06-16T09:26:31","date_gmt":"2023-06-16T07:26:31","guid":{"rendered":"https:\/\/investmentbell.com\/?p=15459"},"modified":"2023-06-16T09:26:34","modified_gmt":"2023-06-16T07:26:34","slug":"gsk-says-fda-extends-review-period-for-experimental-drug-momelotinib","status":"publish","type":"post","link":"https:\/\/investmentbell.com\/ru\/news\/market-overview-news\/gsk-says-fda-extends-review-period-for-experimental-drug-momelotinib\/","title":{"rendered":"GSK \u0441\u043e\u043e\u0431\u0449\u0430\u0435\u0442, \u0447\u0442\u043e FDA \u043f\u0440\u043e\u0434\u043b\u0435\u0432\u0430\u0435\u0442 \u043f\u0435\u0440\u0438\u043e\u0434 \u0440\u0430\u0441\u0441\u043c\u043e\u0442\u0440\u0435\u043d\u0438\u044f \u044d\u043a\u0441\u043f\u0435\u0440\u0438\u043c\u0435\u043d\u0442\u0430\u043b\u044c\u043d\u043e\u0433\u043e \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430 \u043c\u043e\u043c\u0435\u043b\u043e\u0442\u0438\u043d\u0438\u0431\u0430"},"content":{"rendered":"<p>(Reuters) &#8211; British drugmaker GSK Plc on Friday said the U.S. Food and Drug Administration has extended the review period for its experimental drug momelotinib, which is designed to treat anaemic patients with a type of bone marrow cancer called myelofibrosis.<\/p>\n\n\n\n<p>Momelotinib is not currently approved in any market.<\/p>\n<div class=\"rate-now\"><span id=\"rate-mypost15459\"><\/span> <span id=\"rate-points\"> 0<\/span><\/div>\n\t\t\t<script type=\"text\/javascript\">jQuery('#rate-mypost15459').raty({\n\t\t\t\thalfShow : true,\n\t\t\t\thalf: true,readOnly: true,score: 0,\n\t\t\t\tpath: \"https:\/\/investmentbell.com\/wp-content\/plugins\/userpro-rating\/images\/\"\n\t\t\t\t});<\/script>","protected":false},"excerpt":{"rendered":"<p>(Reuters) &#8211; British drugmaker GSK Plc on Friday said the U.S. Food and Drug Administration has extended the review period for its experimental drug momelotinib, which is designed to treat anaemic patients with a type of bone marrow cancer called myelofibrosis. Momelotinib is not currently approved in any market. 0<\/p>","protected":false},"author":13,"featured_media":15460,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[89],"tags":[],"class_list":{"0":"post-15459","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-market-overview-news"},"_links":{"self":[{"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/posts\/15459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/comments?post=15459"}],"version-history":[{"count":0,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/posts\/15459\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/media\/15460"}],"wp:attachment":[{"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/media?parent=15459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/categories?post=15459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/tags?post=15459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}